Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy

被引:0
|
作者
Francesco Testa
Paolo Melillo
Valentina Di Iorio
Claudio Iovino
Francesco Farinaro
Marianthi Karali
Sandro Banfi
Settimio Rossi
Michele Della Corte
Francesca Simonelli
机构
[1] University of Campania Luigi Vanvitelli,Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences
[2] University of Campania Luigi Vanvitelli,Medical Genetics, Department of Precision Medicine
[3] Telethon Institute of Genetics and Medicine,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
To report quantitative retinal changes assessed by spectral-domain optical coherence tomography (SD-OCT) in children treated with voretigene neparvovec (VN) at a single center in Italy. Retrospective review of six consecutive pediatric patients with biallelic RPE65-related dystrophy treated bilaterally with VN. SD-OCT scans were analyzed to extract Early Treatment Diabetic Retinopathy Study (ETDRS) thickness maps of the whole retina and the outer nuclear layer (ONL). Changes in visual function were assessed by best-corrected visual acuity (BCVA) and retinal morphology at Days 30/45 and 180. BCVA significantly improved at Day 30/45 and 6 months (both P < 0.001). Central foveal retinal thickness and central foveal ONL thickness tended to increase (6.4 ± 19.2 µm; P = 0.080 and 3.42 ± 7.68 µm; P = 0.091, respectively). ONL thickness of the internal ETDRS-ring significantly increased at day 30/45 (4.7 ± 8.4 µm; P < 0.001) and day 180 (5.0 ± 5.7 µm; P = 0.009). Intra-operative foveal detachment was not associated with a higher function gain in terms of BCVA, but with a mild thinning of foveal ONL after treatment. The improvement of BCVA and thickening of the ONL layer suggest that improvement of visual acuity could be related to partial recovery of retinal morphology in the perifoveal ring.
引用
收藏
相关论文
共 50 条
  • [21] Correlation of multi-luminance mobility testing with visual function tests in a phase 3 trial of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease
    Chung, Daniel C.
    Russell, Stephen R.
    Bennett, Jean
    Maguire, Albert M.
    Wellman, Jennifer A.
    Yu, Zi-Fan
    Tillman, Amy
    High, Katherine A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [22] Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic RPE65-Mediated Inherited Retinal Dystrophies in a Cohort of Patients from a Single Center
    Kiraly, Peter
    Cottriall, Charles L.
    Taylor, Laura J.
    Jolly, Jasleen K.
    Cehajic-Kapetanovic, Jasmina
    Yusuf, Imran H.
    de la Camara, Cristina Martinez-Fernandez
    Shanks, Morag
    Downes, Susan M.
    MacLaren, Robert E.
    Fischer, M. Dominik
    BIOMOLECULES, 2023, 13 (10)
  • [23] Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland
    Bhadhuri, Arjun
    Droschel, Daniel
    Guldimann, Mike
    Jetschgo, Claudia
    Banhazi, Judit
    Schwenkglenks, Matthias
    Sutherland, C. Simone
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [24] Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland
    Arjun Bhadhuri
    Daniel Dröschel
    Mike Guldimann
    Claudia Jetschgo
    Judit Banhazi
    Matthias Schwenkglenks
    C. Simone Sutherland
    BMC Health Services Research, 22
  • [25] COST-EFFECTIVENESS OF VORETIGENE NEPARVOVEC FOR VISION LOSS DUE TO BIALLELIC RPE65-MEDIATED INHERITED RETINAL DISEASE IN A DANISH SETTING
    Ploug, U.
    VALUE IN HEALTH, 2019, 22 : S846 - S846
  • [26] Retinal Pigment Epithelium Atrophy After Subretinal Voretigene Neparvovec-rzyl for RPE65-Related Disease: A 6-Month Follow-Up
    Giansanti, Fabrizio
    Mucciolo, Dario Pasquale
    Sodi, Andrea
    Giorgio, Dario
    Virgili, Gianni
    Murro, Vittoria
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2022, 42 (12): : E55 - E56
  • [27] Five-year update for the Phase III voretigene neparvovec study in biallelic RPE65 mutation-associated inherited retinal disease
    Leroy, Bart P.
    Russell, Stephen R.
    Bennett, Jean
    High, Katherine A.
    Drack, Arlene V.
    Yu, Zi-Fan
    Chung, Daniel
    Reape, Kathleen Z.
    Maguire, Albert M.
    Simunovic, Matthew
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 49 (08): : 966 - 967
  • [28] Functional outcomes and adverse effects of voretigene neparvovec for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single centre
    Kiraly, Peter
    Cottriall, Charles
    Taylor, Laura J.
    Jolly, Jasleen K.
    Cehajic-Kapetanovic, Jasmina
    Yusuf, Imran H.
    dela Camara, Cristina Martinez-Fernandez
    Shanks, Morag
    Downes, Susan M.
    MacLaren, Robert E.
    Fischer, Dominik M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [29] Three-year update for the phase 3 voretigene neparvovec study in biallelic RPE65 mutation-associated inherited retinal disease
    van den Born, L. Ingeborgh
    Russell, S.
    Bennett, J.
    Chung, D.
    Maguire, A. M.
    ACTA OPHTHALMOLOGICA, 2018, 96 : 28 - 28
  • [30] Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice
    Testa, Francesco
    Bacci, Giacomo
    Falsini, Benedetto
    Iarossi, Giancarlo
    Melillo, Paolo
    Mucciolo, Dario Pasquale
    Murro, Vittoria
    Salvetti, Anna Paola
    Sodi, Andrea
    Staurenghi, Giovanni
    Simonelli, Francesca
    EYE, 2024, 38 (13) : 2504 - 2515